Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
John Williams
Beckman Research Institute/city of Hope, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Meditope Biosciences Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
1. Meditope Biosciences, Inc. is a biotechnology company focused on development of antibody-based cancer products using antibody structural appendages called “meditopes”. Dr. Williams is listed as the Principal Investigator on the funded research grant regarding the use of super-resolution microscopy to systematically optimize multivalent meditopes as leads for cancer therapy and imaging. Dr. Williams’ investment in Meditope Biosciences, Inc. is related to the funded research because in involves the exclusive licensure to Meditope Biosciences, Inc. of a type of meditope technology. The grant will seek novel improvements in the application of meditope science and thus the SFI is relevant to the proposed research work.
2. Meditope Biosciences, Inc. is a biotechnology company focused on the development of antibody-based therapeutic products through use of the meditope technology invented by Dr. Williams. Dr. Williams is listed as the Principal Investigator on this funded research grant which concerns the use of super-resolution microscopy to systematically optimize multivalent meditopes as leads for cancer therapy and imaging. As noted, Dr. Williams’s investment in Meditope Biosciences, Inc. creates a COI that is relevant to the funded research because the aims of the grant may further reduce to practice the meditope technology. Thus, successful completion of the proposed research may have the potential to benefit Meditope Biosciences, Inc., in that it may provide extra validation of the meditope technology which is licensed to them.
Optimization of multivalent ligands by super-resolution microscopy to treat cance
We discovered a novel site within a therapeutic mAb and demonstrated that we can use this site to target tumor cells overexpressing EGFR or Her2 using a multivalent ligand. The goal of this project is to use super-resolution microscopy to quantify EGFR and Her2 receptor density in tumor cells and to use this information to optimize multivalent ligands for enhanced tumor imaging and treatment. Successful application of this technology will be immediately translated to the clinic with the aim of treating colorectal and breast cancers, the second and third most deadly tumor types.
Filed on April 22, 2014.
Tell us what you know about John Williams's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
John Williams filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| John Charles Williams | Beckman Research Institute/city of Hope | Conflict of Interest | City of Hope | >$600,000 |
| John Williams | Beckman Research Institute/city of Hope | Conflict of Interest | Meditope Biosciences Inc. | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.